If you have been reading about PPARδ agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 317318-70-0 | Unique identifier for the compound. |
| Chemical class | PPARδ agonist | Synthetic ligand for peroxisome proliferator-activated receptor delta. |
| Appearance | White to off-white solid | Typical form of research-grade material. |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water. |
| Typical storage | -20°C | Recommended for long-term storage of stock solutions. |
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
During the Perestroika era of the Soviet Union of the late 1980s, many descendants of the Cossacks became enthusiastic about reviving their national traditions. In 1988, the Soviet Union passed a law allowing the reestablishment of former hosts and creation of new ones. The ataman of the largest, the Almighty Don Host, was granted Marshal rank and the right to form a new host. Simultaneously, many attempts were made to increase Cossack's impact on Russian society, and throughout the 1990s many regional authorities agreed to hand over some local administration and policing duties to the Cossacks. According to the 2002 Russian Census, 140,028 people self-identified as ethnic Cossacks. Between 3.5 and 5 million people associate themselves with the Cossack identity in post-Soviet Russia and around the world.
The cephalopod radula consists of multiple symmetrical rows of up to nine teeth – thirteen in fossil classes. The organ is reduced or even vestigial in certain octopus species and is absent in Spirula. The teeth may be homodont (i.e. similar in form across a row), heterodont (otherwise), or ctenodont (comb-like). Their height, width and number of cusps is variable between species. The pattern of teeth repeats, but each row may not be identical to the last; in the octopus, for instance, the sequence repeats every five rows. Cephalopod radulae are known from fossil deposits dating back to the Ordovician. They are usually preserved within the cephalopod's body chamber, commonly in conjunction with the mandibles; but this need not always be the case; many radulae are preserved in a range of settings in the Mason Creek. Radulae are usually difficult to detect, even when they are preserved in fossils, as the rock must weather and crack in exactly the right fashion to expose them; for instance, radulae have only been found in nine of the 43 ammonite genera, and they are rarer still in non-ammonoid forms: only three pre-Mesozoic species possess one.
== Terminology == A child is referred to as the stepdaughter or stepson of their biological or adoptive parent's new spouse, and the spouse is referred to as the stepparent (father or mother) of the child. A stepparent is the spouse of someone's parent, and not their biological parent, stepfather being the male spouse and stepmother the female spouse. A step-grandparent is the step-parent of someone's parent or the parent of one's step-parent, and not someone's biological grandparent, stepgrandfather being the male one, and stepgrandmother the female one. A step-uncle is the spouse of someone's parent's sister (aunt) or brother (uncle) and is not the father of someone's cousin, except when the sibling marries another and never has children (no cousins). The sister's niece/nephew should refer to a new spouse as uncle, not step-uncle. A step-aunt is the spouse of someone's parent's brother (uncle) or sister (aunt) and is not the mother of someone's cousin, except when the sibling marries another and never had children (no cousins). The sister's niece or nephew should refer to the newest spouse as aunt, not step-aunt. Similarly, a stepsibling is the offspring of a stepparent to whom one is not biologically or adoptive related, stepbrother being the male one and stepsister the female one. A stepgrandson is the grandson of someone's spouse who one is not biologically related to. A step-granddaughter is the granddaughter of someone's spouse to whom one is not biologically or adoptive related.
Sources: en.wikipedia.org
=== Public transportation === The NJ Transit 166 bus route provides service to the Port Authority Bus Terminal in Midtown Manhattan, and local service is available on the 753 route. Bus service to Rockland County and the Port Authority Bus Terminal in NYC is also provided by Rockland Coaches route 20/20T.
=== Analgesic === Data from clinical trials have indicated that SNRIs might have pain-relieving properties. Although the perception and transmission of pain stimuli in the central nervous system have not been fully elucidated, extensive data support the roles of serotonin and norepinephrine in pain modulation. Findings from clinical trials in humans have shown that these antidepressants can help to reduce pain and functional impairment in central and neuropathic pain conditions. This property of SNRIs might be used to reduce doses of other pain relieving medication and lower the frequency of safety, limited efficacy, and tolerability issues. Clinical research data has shown that in patients with GAD, duloxetine is significantly more effective than placebo in reducing pain-related symptoms of GAD, after short-term and long-term treatment. However, findings suggested that such symptoms of physical pain recur in relapse situations, which indicate a need for ongoing treatment in patients with GAD and concurrent painful physical symptoms.
Futurist Ray Kurzweil has shown some concern that, within the century, humans may be required to merge with this technology in order to compete in the marketplace. Enhanced individuals have a better chance of being chosen for better opportunities in careers, entertainment and resources. For example, life-extending technologies can increase the average individual life span, affecting the distribution of pension throughout the society. Increasing lifespan will affect human population, further dividing limited resources such as food, energy, monetary resources and habitat. Other critics of human enhancement fear that such capabilities would change, for the worse, the dynamic relations within a family. Given the choices of superior qualities, parents make their child as opposed to merely birthing it, and the newborn becomes a product of their will rather than a gift of nature to be loved unconditionally.
Sources: en.wikipedia.org
7 June Rishi Sunak is criticised for leaving the D-day commemorations early to return to the UK to work on the election campaign. He says: "On reflection, it was a mistake not to stay in France longer – and I apologise." Data produced by Zoopla indicates that rents for new properties rose by 6.6% in the year to April 2024, but that this was the slowest rise in two and a half years. 9 June – Restrictions on carrying more than 100ml of liquid in hand luggage are temporarily reintroduced at some regional airports in order to "enable further improvements to be made" to new checkpoint systems. Those affected are Newcastle, Leeds Bradford, London City, Aberdeen, Southend and Teesside. 10 June – Twenty buildings across the UK are vandalised as part of a co-ordinated attack by Palestine Action, a pro-Palestine group. 11 June A High Court judge rules that convicted sex offender Gary Glitter must pay more than £500,000 to a victim he abused when she was 12 years old. A 28-year-old man is arrested on suspicion of public order offences after objects are thrown at Nigel Farage during a campaign tour in Barnsley. Rishi Sunak unveils the Conservative Party's general election manifesto, which includes a further cut in National Insurance, a halving of immigration, and several new housing policies. Former UN secretary general Ban Ki-moon is awarded the inaugural King Charles III Harmony Award during a ceremony held at St James's Palace. Two animal rights protestors vandalise a portrait of Charles III at London's Philip Mould Gallery by covering it with posters.
Congenital contractural arachnodactyly, also known as Beals–Hecht syndrome Ehlers–Danlos syndrome Homocystinuria Loeys–Dietz syndrome MASS phenotype Multiple endocrine neoplasia, type 2B Shprintzen–Goldberg syndrome Stickler syndrome
== Signs and symptoms == The symptoms of rhabdomyolysis depend on its severity and whether kidney failure develops. Milder forms may not cause any muscle symptoms, and the diagnosis is based on abnormal blood tests in the context of other problems. More severe rhabdomyolysis is characterized by muscle pain, tenderness, weakness, and swelling of the affected muscles. If the swelling is very rapid, as may happen with a crush injury after someone is released from under heavy collapsed debris, the movement of fluid from the bloodstream into damaged muscle may cause low blood pressure and shock. Other symptoms are nonspecific and result either from the consequences of muscle tissue breakdown or from the condition that originally led to the muscle breakdown. Release of the components of muscle tissue into the bloodstream causes electrolyte disturbances, which can lead to nausea, vomiting, confusion, coma or abnormal heart rate and rhythm. The urine may be dark, often described as "tea-colored", due to the presence of myoglobin. Damage to the kidneys may give rise to decreased or absent urine production, usually 12 to 24 hours after the initial muscle damage. Swelling of damaged muscle occasionally leads to compartment syndrome—compression of surrounding tissues, such as nerves and blood vessels, in the same fascial compartment—leading to the loss of blood supply and damage or loss of function in the part(s) of the body supplied by these structures. Symptoms of this complication include pain or reduced sensation in the affected limb.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.
No. Cardarine is not an anabolic steroid; it belongs to a different chemical class that targets PPARδ. Steroids act primarily through androgen receptors, while cardarine acts through a nuclear receptor involved in metabolism.
Some rodent studies reported increased endurance and changes in fat metabolism after cardarine exposure. Long-term studies in animals also raised concerns about cancer in certain tissues. Human trial data are limited, so these findings cannot be directly translated to people.
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.